Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403
milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis
(IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared
with placebo in patients with idiopathic pulmonary fibrosis.